MOSAIC-10YR

Regimen

Experimental
FOLFOX4 (5-FU/LV + oxaliplatin 85 mg/m² Q2W × 12 cycles) — long-term follow-up analysis
Control
FL (fluorouracil + leucovorin) alone — long-term follow-up analysis

Population

Stage II or III colon cancer after curative resection (N=2,246); 10-year follow-up of the MOSAIC trial (long-term follow-up).

Key finding

10-year OS: FOLFOX4 71.7% vs FL 67.1% (HR 0.85, P=.043) overall; Stage II: no OS benefit (79.5% vs 78.4%, HR 1.00); Stage III: OS benefit confirmed (67.1% vs 59.0%, HR 0.80, P=.016). dMMR is independent favorable prognostic factor. FOLFOX benefit applies regardless of BRAF/MMR status in stage III.

Source: PMID 26527776

Timeline

    Guideline citations

    • NCCN Colon (p.93)